RxDoctor Payments DataLook up a doctor →

Andrew Kominsky, MD

Hematology & Oncology · Coeur D Alene, IDNPI 1265478697

Payments from drug & device makers

$13,035in general payments, 2019–2025

Across 575 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Johnson & Johnson$868
  • E.r. Squibb & Sons, L.L.C.$819
  • Pfizer$805
  • Genentech USA, Inc.$512
  • AstraZeneca$505
  • plus $6K from 54 others

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis86$3,222
Johnson & Johnson(2 entities)49$868
E.r. Squibb & Sons, L.L.C.44$819
Pfizer49$805
Genentech USA, Inc.24$512
AstraZeneca(2 entities)23$505
Eisai Inc.23$459
Bristol Myers Squibb27$444
Merck21$443
Incyte Corporation14$283
Lilly USA, LLC12$276
AbbVie10$246
Astellas Pharma US Inc10$237
Takeda Pharmaceuticals U.S.A., Inc.9$229
Sanofi10$208
GSK11$202
Array Biopharma Inc14$192
Regeneron Healthcare Solutions, Inc.8$191
EMD Serono, Inc.8$177
Beigene USA, Inc.6$138
Pharmacyclics LLC, An Abbvie Company5$137
Exelixis Inc.5$136
Seagen Inc.8$135
Tempus AI, Inc5$131
Boehringer Ingelheim5$122
Bayer5$116
Amgen6$109
Progenics Pharmaceuticals, Inc.4$97
Beone Medicines USA, Inc.4$96
Pharmacosmos Therapeutics Inc.4$94
Jazz Pharmaceuticals Inc.3$78
Ipsen Biopharmaceuticals, Inc3$66
Intuitive Surgical1$65
Morphosys, US Inc.3$62
Daiichi Sankyo Inc.3$58
Adaptive Biotechnologies Corporation3$57
Macrogenics, Inc.2$53
Puma Biotechnology, Inc.3$51
Myriad Genetic Laboratories, Inc.3$50
Accord Healthcare, Inc.2$47
Springworks Therapeutics, Inc.2$47
Spectrum Pharmaceuticals Inc.2$45
Sumitomo Pharma America, Inc.2$44
Mirati Therapeutics, Inc.2$44
Karyopharm Therapeutics Inc.2$43
AVEO Pharmaceuticals, Inc.2$42
Sobi, Inc1$41
Servier Pharmaceuticals LLC2$40
Alnylam Pharmaceuticals Inc.2$34
Fresenius Kabi USA, LLC2$33
Stryker1$31
CTI Biopharma Corp.1$28
Verity Pharmaceuticals Inc.1$26
Iovance Biotherapeutics, Inc.1$25
Dendreon Pharmaceuticals LLC1$23
G1 Therapeutics, Inc.1$23
Taiho Oncology, Inc.1$23
Kyowa Kirin, Inc.1$22
Telix Pharmaceuticals1$20
Acrotech Biopharma Inc.1$20

How this compares

$13,035 in reported general payments places this provider in the 55th percentile of 34 hematology & oncology providers in Idaho.

See all hematology & oncology providers in Idaho →

Medicare billing

Part B allowed, 2024
$2,141,450
Medicare patients
376
Services billed
56,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Coeur D Alene

See the full list for Idaho →

Where these figures come from

Is this you, or does something look wrong? →